Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Till Seiler"'
Autor:
Maria Göbel, Lewin Eisele, Michael Möllmann, Andreas Hüttmann, Patricia Johansson, René Scholtysik, Manuela Bergmann, Raymonde Busch, Hartmut Döhner, Michael Hallek, Till Seiler, Stephan Stilgenbauer, Ludger Klein-Hitpass, Ulrich Dührsen, Jan Dürig
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e72107 (2013)
Progranulin (Pgrn) is a 88 kDa secreted protein with pleiotropic functions including regulation of cell cycle progression, cell motility, wound repair and tumorigenesis. Using microarray based gene expression profiling we have recently demonstrated t
Externí odkaz:
https://doaj.org/article/9703eff2c92f44caa45af17aed231c40
Autor:
Anna-Maria Fink, Marco Herling, Till Seiler, Sebastian Oberbeck, Thorsten Zenz, Georg Hopfinger, Petra Mayer, Sandra Robrecht, Anne Westermann, Natali Pflug, Paula Cramer, Jan Dürig, Michael Hallek, Jasmin Bahlo, Karl-Anton Kreuzer, Stephan Stilgenbauer, Alexandra Schrader, Barbara Eichhorst
Publikováno v:
Leukemia & Lymphoma. 60:649-657
Clinical trials in T-cell prolymphocytic leukemia (T-PLL) are scarce. Based on a precursor study testing fludarabine, mitoxantrone, and cyclophosphamide followed by alemtuzumab (FMC-A), we aimed to improve this regimen by upfront combining subcutaneo
Autor:
Sebastian Böttcher, Barbara Eichhorst, Othman Al-Sawaf, Petra Langerbeins, Anja Engelke, Matthias Ritgen, Jasmin Bahlo, Eugen Tausch, Michael Hallek, Holger Hebart, Sandra Robrecht, Michael Kneba, Paula Cramer, Anna-Maria Fink, Stephan Stilgenbauer, Kirsten Fischer, Till Seiler, Ludwig Fischer von Weikersthal, Clemens-Martin Wendtner, Julia von Tresckow, Karl-Anton Kreuzer
Publikováno v:
The Lancet Oncology. 19:1215-1228
Summary Background Targeted agents such as the type II anti-CD20 antibody obinutuzumab and the B-cell lymphoma-2 antagonist venetoclax have shown impressive therapeutic activity in chronic lymphocytic leukaemia. The CLL2-BAG trial was initiated to in
Publikováno v:
Drugs. 76:639-646
The phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway is implicated in the pathogenesis of lymphoma. Deeper understanding of the diversity and biological impact of this pathway has led to the development of specific inhibitors to this pathway. Precli
Autor:
Othman Al-Sawaf, Michael Kneba, Till Seiler, Petra Langerbeins, A. M. Fink, Sandra Robrecht, C M Wendtner, Jasmin Bahlo, Paula Cramer, Michael Hallek, Kirsten Fischer, S. Stilgenbauer, Matthias Ritgen, L. Fischer von Weikersthal, Anja Engelke, Barbara Eichhorst, J. von Tresckow, Karl-Anton Kreuzer, Holger Hebart
Publikováno v:
Hematological Oncology. 35:25-27
Autor:
Christian Weber, Kristina Busygina, Reinhard Lorenz, Till Seiler, Richard Brandl, Janina Jamasbi, Wolfgang Siess, Hans Deckmyn
Publikováno v:
Blood, 131(24), 2605-2616. The American Society of Hematology
Interaction of von Willebrand factor (VWF) with platelet glycoprotein lb (GPIb) and interaction of collagen with GPVI are essential for thrombus formation on ruptured or eroded atherosclerotic plaques (atherothrombosis). GPIb and GPVI signal through
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88eb4e6bdbf3a1b0df6d8005639751d9
https://cris.maastrichtuniversity.nl/en/publications/8d5ddf5b-54c5-42df-80e7-f776d6b75933
https://cris.maastrichtuniversity.nl/en/publications/8d5ddf5b-54c5-42df-80e7-f776d6b75933
Autor:
Barbara Eichhorst, Ulrich Jäger, K. Fischer, Georg Hopfinger, Ethan M. Lange, Michael Kneba, P. Cramer, Valentin Goede, Manuela Bergmann, Jasmin Bahlo, C M Wendtner, A.-M. Fink, Othman Al-Sawaf, Michael Hallek, S. Stilgenbauer, Christian Maurer, Till Seiler, Michael G. Kiehl, Sandra Robrecht, Hartmut Döhner, J. von Tresckow
Publikováno v:
Leukemia. 31(10)
Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group
Autor:
Simon Warburton, Jasmin Bahlo, Eugen Tausch, Sebastian Böttcher, Kirsten Fischer, Javier López, Thomas J. Kipps, Michael Hallek, Lukas Frenzel, Matthias Ritgen, Valentin Goede, Othman Al-Sawaf, Sue Robinson, Anna-Maria Fink, Jacque J.M. Van Dongen, Anton W. Langerak, Stephen Opat, Kathryn Humphrey, Clemens M. Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Mark Dixon, Carolyn Owen, Rod A. Humerickhouse, Till Seiler, Robert Weinkove, Mehrdad Mobasher
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Blood, 129(19), 2702-2705. American Society of Hematology
Consejería de Sanidad de la Comunidad de Madrid
Blood, 129(19), 2702-2705. American Society of Hematology
To the editor: In chronic lymphocytic leukemia (CLL), the median age at diagnosis is 72 years, and most patients requiring therapy have coexisting medical conditions. Venetoclax is a potent BH3-mimetic compound that selectively antagonizes BCL-2 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acc05c7b1b81cb997630e4809873e0a7
https://saludmadrid.ibai.com/handle/20.500.12530/32342
https://saludmadrid.ibai.com/handle/20.500.12530/32342
Autor:
Anja Engelke, S. Stilgenbauer, A. M. Fink, Jasmin Bahlo, Gbor Kovacs, C M Wendtner, Michael Hallek, Petra Langerbeins, Matthias Ritgen, Barbara Eichhorst, Kirsten Fischer, Natali Pflug, Till Seiler, Lutz P. Müller, J. von Tresckow, Christian Maurer, Paula Cramer
Publikováno v:
Leukemia. 30(10)
This study aimed to assess the frequency of and the contributing factors for second primary malignancies (SPMs) and Richter's transformations (RTs) following first-line treatment of chronic lymphocytic leukemia within four phase II/III trials of the
Autor:
Till Seiler, Tobias Herold, Nicole Schinwald, Manuela Bergmann, Martin Dreyling, Christian Buske, Rupert Egensperger, Friederike F. H. Mumm, Daniel Franke, Christoph Trumm
Publikováno v:
Leukemia & Lymphoma. 53:169-172
With the introduction of potent immunosuppressive agents, progressive multifocal leukoencephalopathy (PML) as a lethal complication of immune suppression has gained more and more attention during recent years [1]. PML is a mostly fatal, demyelinating